_ OCULUS BIO MED
THE TEAM
Meet our team who are seeking to change the treatment paradigm for patients suffering from debilitating and degenerative ocular diseases.
Pioneering therapies and advancing innovative ocular treatments requires the right people – smart, diligent and creative individuals who collaborate and drive to achieve what has not yet been done.
We integrate environmental, social and governance into our decision-making and see strength in diversity and inclusiveness. This diversity and experience of the team stimulates communication, problem solving and creativity.
_ LEADERSHIP TEAM
Oculus Biomed Leadership Team
Dr. R Ou
MBBS, MD, MAICD
Executive Chairman
Dr. Ou has extensive strategic and operational experiences in the life sciences and technology industries. In particular, research innovation, clinical trial activities, management structuring, commercialization and medical device development.
In the early years of his professional career, Dr. Ou worked as a Cardiac Surgeon in China, a MD Fellow in Cardiology, University of Missouri-Columbia, USA and as a senior research scientist in the Baker Heart and Diabetes Institute, Australia. Dr. Ou conducted ground-breaking work in donor organ preservation, devised the world’s first miniature myocardial pH electrode and involved in the development of ventricular assist device, key-hole heart surgery instruments and heparin-free oxygenator, etc..
Dr. Ou holds the senior positions in many prestigious organizations. He is the honorary Associate of the Baker Heart and Diabetes Institute, sits on the Board of Access Asia Health Accelerator, serves as the Biomedical Advisor to Eureka Technology Innovation and Investment and Chairs the Advisory Board of Eureka Research Fund. Dr Ou is the Emeritus National President of Australia Chinese Association for Biomedical Sciences.
Mr A. J. Coloretti
B Bus. Grad Dip. FIPA FGIA
CEO / Executive Director
Andrew has had a nearly 30-year career in leadership positions. His experience includes roles in executive management, R&D, boards, and business development in corporate, asset management, biotech academia and philanthropy. During his career he has managed businesses, negotiated and executed strategic corporate transactions, including mergers and acquisitions, portfolio management and licensing.
Previous roles include CIO of Separtis (E-Waste / PFAS technology), Corporate Adviser to Defugo Bioceuticals, Executive Director of Aura Group, CEO / CIO of Giles Wade, CEO of Boston Capital Group, and Co-founder of Rocking Horse Group (R & D financier). Also, over the span of his career, he has held roles of increasing responsibility at several companies, including HSBC and Chimaera Group.
Andrew received a Bachelor of Business and Post Graduate Diploma from Monash University. He is a Fellow of both The Governance Institute of Australia (FGIA) and Institute of Public Accountants (FIPA).
Mr R. McPherson
B Bus, GAICD, CPA
CFO / Company Secretary
Roger has more than 30 years’ experience as a CPA in senior finance roles including CFO and Company Secretarial services for both listed and unlisted entities across a variety of industries including pharmaceutical and biotech.
Prior to joining Oculus, Roger was CFO and Company Secretary for a number of SMEs both listed and unlisted including Bio-Gene Technology Ltd and Patrys Ltd. In these roles he was responsible for all financial affairs and corporate administration as well as assisting in investor relations activities.
Mr C. C. Chang
B. Finance, MBA, MAICD
COO / Executive Director
Mr Chang has had a nearly 30-year career in leadership positions and held roles in executive management, finance, taxation and boards.
Previous roles include Financial Accountant of Golden Circle/Heinz Corp Australia, Project Manager of Oracle Korea, Financial Manager of Reuters Korea, and Accountant of LG Korea.
Mr Chang received a MBA degree from Monash University, a Bachelor degree in Accounting/Business from Hanyang University, Seoul, Korea, an Advanced Diplomat of Financial Planning from Kaplan, and Professional Level of CPA Program, Melbourne. He is a Certificated Professional Accountant, a Registered Tax Agent, a Financial Service Licensee, and a member of Australian Institute of Company Director (MAICD).
Mr J. W. Jiang
BS, MS, PhD
Chief Scientific Officer & Head of Research and Development
Dr Jiang has had over 20 years of experience in the Australian biotechnology industry. In particular, working on peptides and small molecules into therapeutics for several different indications.
His experience included development of synthetic peptide into anti-obesity drug from discovery through successful Phase 2A clinical trials, a small molecule into a repurposed drug for asthma, participation of a project to develop a small molecule, muparfostat, with anti-angiogenic and anti-metastatic activities into a drug for hepatocellular carcinoma through Phase 3 clinical trial and leading a team of CDMO company to develop in all facets of CMC for successful manufacture of muparfostat under cGMP for the use of conducting Phase 3 clinical trial.
Previous roles include Assistant Scientist of Development Center for Biotechnology in Taiwan, Founding Scientist of former ASX-listed Metabolic Pharmaceutical Limited (later reverse-takeover by PolyNovo Limited, ASX: PNV), CEO of Wholesome Biopharm Pty Ltd, Director of former ASX-listed Progen Pharmaceutical Limited and Managing Director of PharmaSynth Pty Ltd.
Dr Jiang holds a PhD in Biochemistry and Molecular Biology from the Faculty of Medicine, Monash University and a Master degree and a Bachelor degree, both from Faculty of Science, National Cheng Kung University, Taiwan. He is a member of the Drug Information Association (DIA), a global, member-driven organization mobilizing life sciences and healthcare professionals.
Mr J. Q. Liang
B.A (Finance), MAICD
Vice President – Business Development
Mr Liang has over 25 years experience in executive management and at board level. His experience ranges from strategic planning, project management, operational and business development in both the corporate and at the community level.
Previous roles include a long tenure as a senior executive of SDG Group, covering manufacturing, property, retail and petroleum. Also, as Executive Chairman of Sunbird Australia Pty Ltd, and Executive Director of AusBioLink Pty Ltd with a focus on establishing and managing partnerships in the biomedical industry.
In addition to his corporate experience, Mr Liang has extensive experience and impact in the Not-For-Profit and business community association arena. He is the current Executive Vice-President of the Shenzhen Business Association Australia and an Executive Board member of the Chinese Association of Victoria Inc. Previously, he was the Executive Vice-President of The Federation Chinese Association (FCA) of Victoria.
Mr Liang received an Associate Degree in Finance, Securities Finance from ShenZhen Open University, China.
He is a member of of Australian Institute of Company Director (MAICD).
_ SCIENTIFIC BOARD & ADVISORY
Prof. Robyn Guymer AM
MBBS, PhD, FRANZCO, FAHMS
Chief Advisor, Clinical & Medical Research
Experience
- Deputy Director, Head of Macular Research – Centre Eye Research Australia (CERA)
- Professor of Ophthalmology at Melbourne University
- Senior retinal specialist at the Royal Victorian Eye and Ear Hospital
- She is on several pharmaceutical advisory boards and is part of the Mactel consortium, the Beckman/Ryan AMD initiative (USA) and the International Classification of Atrophy (CAM) Group
- Member in the General Division (AM) in the 2018 Queen’s Birthday Honours List
- Awarded the NHMRC’s 2016 Elizabeth Blackburn Fellowship for the top ranked female research fellowship in clinical medicine
Prof. Mingguang He
MD, PhD, FRANZCO
Advisor, Clinical Research
Experience
- Professor, Ophthalmic Epidemiology at the University of Melbourne, Australia
- Head of Ophthalmic Epidemiology, Centre for Eye Research Australia
- Director, WHO Collaborating Centre for the Prevention of Blindness in Western Pacific Region
- Fellow, Royal Australian and New Zealand College of Ophthalmologists
Dr. Marrisa Lim
MBBS, MBA
Advisor, Medical Product Development
Experience
- Director, Catori Consulting
- Former Global Medical Director, Telix Pharmaceuticals Limited (ASX: TLX)
- Former Medical Director, Australia, New Zealand, Ipsen Pty Ltd
- Former Medical Director, Vifor Pharma Pty Ltd
- Former Associate Director, Medical Affairs, Hospira (now part of Pfizer)
Prof. Yeou-Ping Tsao
MBBS, PhD
Chief Advisor, Scientific & Medical Research
Experience
- Section Chief & Principal Investigator, Departments of Medical Research & BioMedical Development Center, MacKay Memorial Hospital, Taipei, Taiwan
- Professor and Attending physician, Department of Ophthalmology, MacKay Memorial Hospital, Taipei, Taiwan
- Member of American Academy of Ophthalmology (AAO)
Prof. Yao Xiaoming
BS, MD
Advisor, Clinical Research
- Vice President & Chief Physician of Shenzhen Huaxia Eye Hospital, China
- Director of Eye Banking Department, China Huaxia Eye Hospital Group
- Vice President, Society of Organ & Tissue Donation
- Former Associate Professor, Medical College of Ji'nan University, Shenzhen, China
Ms. Fiona Wu
LLB
Advisor, Cross-Border Business Research
- Poly Auction Hong Kong
- Doctor of Law Candidate at Northwestern Pritzker School of Law, Chicago, USA
- Bachelors of Law Degree - IE University, Madrid, Spain
- Global Brain Data Foundation
_ PARTNERSHIPS
Scientific / Research
Centre for Eye research Australia (CERA) 
Established in 1996 by Melbourne Laureate Professor Hugh Taylor, CERA has grown into an international leader in vision research. CERA’s research expanded to encompass stem cell, pharmacology and drug delivery research, as well as groundbreaking projects such as the bionic eye. It continues to be Collaborating Centre for the Prevention of Blindness by the World Health Organisation (WHO), the only such centre in Australia. CERA is an independent medical research institute, affiliated with the University of Melbourne. It is based at the Royal Victorian Eye and Ear Hospital in Melbourne City, Australia.
Mackay Memorial Hospital (MMH) 
Established on 26 December 1912, MMH is one of the largest medical centers in Taiwan. MMH was founded on the basis of Jesus’ universal love and for the memory on George Leslie Mackay who was the first modern missionary from Canada to northern Taiwan. It is a private Christian hospital group which operates 5 large hospitals and state-of-the-art medical research facilities and innovation incubation centre in Taiwan under the spiritual guidance of the Presbyterian Church in Taiwan.
ACRO Biomedical Co., Ltd. (ACRO) 
ACRO is a public listed clinical-stage biomedical company on the Emerging Stock Board (ESB) of the Taipei Exchange (TPEx) with the code 6748. Established in June 2014, ACRO aims to develop medical-grade regenerative biomaterials. These biomaterials in development will be used for tissue repairs in areas such as ophthalmology, orthopedics, dentistry, cardiovascular grafts, surgeries, wound repairs, sports injuries, and etc. It has received FDA’s 510k approval for a few of their products, including Bone Matrix products.
Krisan Biotech Co., Ltd. (Krisan) 
Founded in August, 2015, Krisan is located in Tainan Science Park, Taiwan. KriSan has a group of professional team with 10+ years API experiences in average. KriSan engages in development and production of APIs with high technical barriers and provides world-class services, which include process R&D, analytical method R&D and validation, CGMP production, CMC compiling and regulatory consultation. KriSan targets two market segments in the global pharmaceutical industry for (i) Customized CRO/CDMO/CMO services, including the supply of gram to kilogram quantities of small molecule, peptide, and peptide-drug conjugate (PDC) from pre-clinical through phase 2 stages, and (ii) Generic API manufacturing.
Professional Services
